NIKKEI 225
26,859.18 +199.43 (+0.75%) HANG SENG
20,596.37 -6.15 (-0.03%) CRUDE OIL
113.88 +1.48 (+1.32%) GOLD FUTURES
1,808.70 -10.20 (-0.56%) DOW
32,654.59 +431.17 (+1.34%) BTC-GBP
24,057.84 -440.84 (-1.80%)
Pharvaris N.V. (PHVS)
| Previous close | 17.11 |
| Open | 17.10 |
| Bid | 7.02 x 2900 |
| Ask | 28.08 x 1800 |
| Day's range | 17.10 - 17.55 |
| 52-week range | 13.14 - 22.24 |
| Volume | |
| Avg. volume | 15,073 |
| Market cap | 581.825M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings date | 24 May 2022 - 30 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.50 |
- Globe Newswire
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced company-wide support of today’s Hereditary Angioedema International (HAEi) hae day :-) 2022, a global awareness day for hereditary angioedema (HAE). Pharvaris supported the HAE community by partaking in the hae day :-) Activ
- Globe Newswire
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the appointment of Joan Schmidt, J.D., to the newly created position of Chief Legal Officer,
- Globe Newswire
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment underway in HAE CHAPTER-1, proof-of-concept Phase 2 prophylactic study using PHVS416 for the prevention of HAE attacks; top-line data anticipated in 4Q22 RAPIDe-2, long-term extension on-demand study of PHVS416 for the treatment of HAE attacks, on-track to initiate in 2H22Continue to execute from a strong financial position with cash and cash eq
